ase (Remicade), cancer (Zytig a, Velcade), schizophrenia (Risperdal), diabetes (Invokana), psoriasis (Stela ra), migraines (Topamax), heart disease (Xarelto) and attention deficit disorder (Concerta). As of the start of this summer the company had to new drugs in the pipeline that might achieve more tha